Roche has announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy (GA), the advanced form of age-related macular degeneration (AMD).

 The phase III study program will evaluate the safety and efficacy of lampalizumab and its potential to slow the progression of GA.